| Patient | Race/sex | Specific ENA | Rituximab dose | Peak HACA (ng/ml) | Drug at week 15 | B cell depletion | Response to immunisation PV/TT | FcγRIIIa allele |
| 001 | A/F | Sm, Ro | Low | 1890 | – | – | – | – |
| 002 | C/F | Ro | Low | 169 | – | – | – | FF |
| 003 | C/F | None | Full | 0 | Yes | Full | No/no | – |
| 004 | A/F | Ro | Full | 0 | Yes | Full | No/no | FF |
| 005 | A/F | None | Full | 33 | No | Short lived | Yes/yes | VV |
| 006 | A/F | None | Full | 66 | Yes | Full | – | FV |
| 007 | A/F | RNP, La | Full | 78 | No | Short lived | – | FF |
| 008 | C/F | RNP | X2 | 0 | No | Full | – | FV |
| 009 | C/M | Ro, La | Full | 0 | Yes | Full | – | FF |
| 010 | C/F | None | X3 | 0 | – | – | – | – |
| 011 | C/F | Sm, RNP, Ro | Full | 153 | Yes | Short lived | Yes/yes | FV |
| 012 | A/F | Sm | Full | 278 | No | Short lived | Yes/no | FV |
| 013 | A/F | Ro | Full | 0 | No | Short lived | No/no | VV |
| 014 | C/F | None | Full | 0 | – | Full | No/no | FV |
| 015 | A/F | Sm | Full | 148 | No | Partial | No/no | FV |
| 016 | C/F | None | Full | 0 | – | Full | No/no | FF |
| 017 | A/F | Ro | Full | 0 | – | – | – | – |
| 018 | C/F | Ro, La | Full | 136 | Yes | Full | No/no | FF |
| 019 | C/F | Ro | Full | 0 | Yes | Short lived | No/yes | FF |
| 020 | C/F | Sm | X2 | 28 700 | No | Short lived | No/no | FF |
| 021 | C/F | None | X1 | 0 | – | – | – | – |
| 022 | A/F | None | Full | 0 | Yes | Full | No/no | FF |
| 023 | C/F | None | Full | 0 | No | Full | Yes/yes | FV |
| 024 | A/M | Sm | X1 | 0 | No | Full | No/yes | FF |
A, African–American; C, Caucasian; ENA, extractable nuclear antigen/antibody; F, female; HACA, human anti-chimeric antibody; La, Sjögren syndrome B; M, male; RNP, ribonucleoprotein; Ro, Sjögren syndrome A; Sm, Smith; C, Caucasian. PV, Pneumovax; TT, tetanus toxoid.